Cargando…

A genomics-based systems approach towards drug repositioning for rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of synovial joints. RA affects up to 1 % of the population worldwide. Currently, there are no drugs that can cure RA or achieve sustained remission. The unknown cause of the disease re...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Rong, Wang, QuanQiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001200/
https://www.ncbi.nlm.nih.gov/pubmed/27557330
http://dx.doi.org/10.1186/s12864-016-2910-0
_version_ 1782450428742467584
author Xu, Rong
Wang, QuanQiu
author_facet Xu, Rong
Wang, QuanQiu
author_sort Xu, Rong
collection PubMed
description BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of synovial joints. RA affects up to 1 % of the population worldwide. Currently, there are no drugs that can cure RA or achieve sustained remission. The unknown cause of the disease represents a significant challenge in the drug development. In this study, we address this challenge by proposing an alternative drug discovery approach that integrates and reasons over genetic interrelationships between RA and other genetic diseases as well as a large amount of higher-level drug treatment data. We first constructed a genetic disease network using disease genetics data from Genome-Wide Association Studies (GWAS). We developed a network-based ranking algorithm to prioritize diseases genetically-related to RA (RA-related diseases). We then developed a drug prioritization algorithm to reposition drugs from RA-related diseases to treat RA. RESULTS: Our algorithm found 74 of the 80 FDA-approved RA drugs and ranked them highly (recall: 0.925, median ranking: 8.93 %), demonstrating the validity of our strategy. When compared to a study that used GWAS data to directly connect RA-associated genes to drug targets (“direct genetics-based” approach), our algorithm (“indirect genetics-based”) achieved a comparable overall performance, but complementary precision and recall in retrospective validation (precision: 0.22, recall: 0.36; F1: 0.27 vs. precision: 0.74, recall: 0.16; F1: 0.28). Our approach performed significantly better in novel predictions when evaluated using 165 not-yet-FDA-approved RA drugs (precision: 0.46, recall: 0.50; F1: 0.47 vs. precision: 0.40, recall: 0.006; F1: 0.01). CONCLUSIONS: In summary, although the fundamental pathophysiological mechanisms remain uncharacterized, our proposed computation-based drug discovery approach to analyzing genetic and treatment interrelationships among thousands of diseases and drugs can facilitate the discovery of innovative drugs for treating RA.
format Online
Article
Text
id pubmed-5001200
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50012002016-09-06 A genomics-based systems approach towards drug repositioning for rheumatoid arthritis Xu, Rong Wang, QuanQiu BMC Genomics Research BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of synovial joints. RA affects up to 1 % of the population worldwide. Currently, there are no drugs that can cure RA or achieve sustained remission. The unknown cause of the disease represents a significant challenge in the drug development. In this study, we address this challenge by proposing an alternative drug discovery approach that integrates and reasons over genetic interrelationships between RA and other genetic diseases as well as a large amount of higher-level drug treatment data. We first constructed a genetic disease network using disease genetics data from Genome-Wide Association Studies (GWAS). We developed a network-based ranking algorithm to prioritize diseases genetically-related to RA (RA-related diseases). We then developed a drug prioritization algorithm to reposition drugs from RA-related diseases to treat RA. RESULTS: Our algorithm found 74 of the 80 FDA-approved RA drugs and ranked them highly (recall: 0.925, median ranking: 8.93 %), demonstrating the validity of our strategy. When compared to a study that used GWAS data to directly connect RA-associated genes to drug targets (“direct genetics-based” approach), our algorithm (“indirect genetics-based”) achieved a comparable overall performance, but complementary precision and recall in retrospective validation (precision: 0.22, recall: 0.36; F1: 0.27 vs. precision: 0.74, recall: 0.16; F1: 0.28). Our approach performed significantly better in novel predictions when evaluated using 165 not-yet-FDA-approved RA drugs (precision: 0.46, recall: 0.50; F1: 0.47 vs. precision: 0.40, recall: 0.006; F1: 0.01). CONCLUSIONS: In summary, although the fundamental pathophysiological mechanisms remain uncharacterized, our proposed computation-based drug discovery approach to analyzing genetic and treatment interrelationships among thousands of diseases and drugs can facilitate the discovery of innovative drugs for treating RA. BioMed Central 2016-08-22 /pmc/articles/PMC5001200/ /pubmed/27557330 http://dx.doi.org/10.1186/s12864-016-2910-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Xu, Rong
Wang, QuanQiu
A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
title A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
title_full A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
title_fullStr A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
title_full_unstemmed A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
title_short A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
title_sort genomics-based systems approach towards drug repositioning for rheumatoid arthritis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001200/
https://www.ncbi.nlm.nih.gov/pubmed/27557330
http://dx.doi.org/10.1186/s12864-016-2910-0
work_keys_str_mv AT xurong agenomicsbasedsystemsapproachtowardsdrugrepositioningforrheumatoidarthritis
AT wangquanqiu agenomicsbasedsystemsapproachtowardsdrugrepositioningforrheumatoidarthritis
AT xurong genomicsbasedsystemsapproachtowardsdrugrepositioningforrheumatoidarthritis
AT wangquanqiu genomicsbasedsystemsapproachtowardsdrugrepositioningforrheumatoidarthritis